Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1/2 4Phase 3 3Phase 1 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 11Active not recruiting 11Completed 4Not yet recruiting 3Unknown 2Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Neoplasm, Residual 1NSCLC 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Capecitabine 25Oxaliplatin 24Paclitaxel 23Gemcitabine 21Cisplatin 21Fluorouracil 20Carboplatin 18Drug Therapy 17Docetaxel 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Injections 10Radiation 9Pemetrexed 9Magnetic Resonance Spectroscopy 9Bevacizumab 9toripalimab 8Cetuximab 8Surgical Procedures, Operative 7Specimen Handling 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6atezolizumab 6Topotecan 6Cyclophosphamide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × osimertinib × Clear all
NCT07376382 2026-05-13

SYNSTAR-02

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
680 enrolled
Thoracic

NSCLC

NCT06380348 2024-04-23

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Shanghai JMT-Bio Inc.

Phase 3 Not yet recruiting
398 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06323148 2024-03-21

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Fudan University

Phase 3 Not yet recruiting
226 enrolled
Thoracic

Lung Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡